Dupont Jakob 4

What Happened Jakob Dupont, a director of Pyxis Oncology (PYXS), received a grant/award on 2026-03-24 covering 45,867 shares (reported as a derivative acquisition at $0.00). The filing shows a grant (code A) with no immediate cash value reported; the award will vest 100% on the first anniversary of the grant date, subject to continued service.

Key Details

• Transaction date: 2026-03-24; Form 4 filed: 2026-03-25 (timely filing).
• Transaction type: Grant/award of a derivative instrument (reported as 45,867 shares @ $0.00).
• Vesting: 100% vests on the first anniversary of the grant (footnote).
• Shares owned after transaction: Not specified in the provided excerpt.
• Other notes: No 10b5-1, tax-withholding, or cashless-exercise details were listed in the provided data.

Context This was a compensation-related derivative grant (likely stock options or similar) that does not represent an immediate purchase or sale of shares. Because the award vests in one year and is subject to continued service, it is not immediately realizable and should be viewed as part of ongoing executive/director compensation rather than a direct market signal.